SCHEMBL3638259

SCHEMBL3638259

COC(=O)CC(O)CNS(=O)(=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
MMP13 P45452 1/20 0.50
THRB P10828 1/20 0.50
CYP19A1 P11511 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
LMNA P02545 2/20 0.47
SLC10A6 Q3KNW5 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PKM P14618 1/20 0.46
F2 P00734 1/20 0.45
PRSS1 P07477 1/20 0.45
PRSS2 P07478 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3104112 0.83 CA1 (0.52) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL5201127 0.82 CA1 (0.57) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL31120657 0.82 CA1 (0.57) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL25353051 0.81 CA1 (0.52) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL30449084 0.81 CA1 (0.52) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL4172892 0.80 KMT2A (0.56) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL12610576 0.80 ALDH1A1 (0.49) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL5848761 0.80 ALDH1A1 (0.56) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL30299066 0.80 ALDH1A1 (0.46) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL6914982 0.80 CA1 (0.51) ALDH1A1CA1CA2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317697-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-12-16 US disclosed
US-20100317697-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-12-16 US disclosed
US-20100317697-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-12-16 US disclosed
US-20100280005-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-11-04 US disclosed
US-20100280005-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-11-04 US disclosed
US-20100280005-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-11-04 US disclosed
EP-2167609-A1 RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2010-03-31 EP disclosed
WO-2009096996-A1 RENIN INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-06 WO disclosed
WO-2009096996-A1 RENIN INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-06 WO disclosed
WO-2008124577-A1 RENIN INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-10-16 WO disclosed
WO-2008124577-A1 RENIN INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280005-A1 Renin Inhibitors REN, ACE, AGTR1 ALDH1A1 1651/4885CA1 1575/4885CA2 1426/4885
US-20100317697-A1 Renin Inhibitors REN, ACE, SERPINB1 ALDH1A1 1056/4885CA1 1461/4885CA2 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.